In this article, we report the design, synthesis, biological activity, and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX is a new approach with potential to deliver organometallic, drug-like compounds as future therapies.
Salmon, A. J., Williams, M. L., Wu, Q. K., Morizzi, J., Gregg, D. J., Charman, S. A., ... Poulsen, S-A. (2012). Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. Journal of Medicinal Chemistry, 55(11), 5506 - 5517. https://doi.org/10.1021/jm300427m